scholarly journals A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival

2019 ◽  
Vol 10 (22) ◽  
pp. 5427-5433
Author(s):  
Abhinav Kurumaddali ◽  
Ahmed Hamed Salem ◽  
Suresh K. Agarwal
Keyword(s):  
Overall Survival ◽  
Myelodysplastic Syndrome ◽  
Meta Analysis ◽  
Short Term ◽  
The Relationship

scholarly journals Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Bogdan Silviu Ungureanu ◽  
Cristian-Virgil Lungulescu ◽  
Daniel Pirici ◽  
Adina Turcu-Stiolica ◽  
Dan Ionut Gheonea ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Targeted Therapy ◽  
Odds Ratio ◽  
Web Of Science ◽  
Meta Analysis ◽  
Pathological Features ◽  
Potential Efficacy ◽  
The Relationship ◽  
Review Manager

An increasing number of tumor markers have been discovered to have potential efficacy as diagnostic and prognostic tools in gastric cancer. We aimed to assess putative correlations between claudin 18.2 expression and pathological or prognosis features in patients with gastric cancer. MEDLINE, Web of Science, EBSCO, and ClinicalTrials.gov were used to search for relevant studies from their inception to 30 October 2020. Finally, a total of six articles were included in this meta-analysis. Review Manager 5 software was applied to examine the heterogeneity among the studies and to calculate the odds ratio with 95% CI by selecting corresponding models, in evaluating the strength of the relationship. Publication bias test was also conducted. No bias and no significant correlations were found between CLDN 18.2 and TNM stages, Lauren classification, HER2, grading, or overall survival. This meta-analysis expounded that the relationship with CLDN 18.2 and pathological features depends on the percentage of staining of tumor cells for which CLDN 18.2 is considered positive. Our pooled outcomes suggest that targeted therapy for CLDN 18.2 could be effective if certain criteria were established.

scholarly journals Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yongfeng Wang ◽  
Liangyin Fu ◽  
Tingting Lu ◽  
Guangming Zhang ◽  
Jiawei Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tumor Marker ◽  
Meta Analysis ◽  
Clinicopathological Features ◽  
High Expression ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Early Cancer Diagnosis ◽  
Patient Prognosis ◽  
The Relationship

Background: Although the treatment of cancer has made evident progress, its morbidity and mortality are still high. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. Therefore, it is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis.Methods: We searched PubMed, Embase, Web of Science, and The Cochrane Library from inception to September 2020 to identify correlational studies. Then, we extracted valid data and used Stata software to make forest plots. We used the hazard ratio (HR) or odds ratio (OR) with 95% CI to evaluate the relationship between aberrant expression of MIAT and patients' prognosis and clinicopathological features.Results: The study included 21 studies, containing 2,048 patients. Meta-analysis showed that overexpression of lncRNA MIAT was associated with poor overall survival (OS) (HR = 1.60, 95% CI, 1.31–1.96, p < 0.001). In addition, high expression of MIAT could forecast tumor size (OR = 2.26, 95% CI 1.34–3.81, p = 0.002), distant metastasis (OR = 2.54, 95% CI 1.84–3.50, p < 0.001), TNM stage (OR = 2.38, 95% CI 1.36–4.18, p = 0.002), lymph node metastasis (OR = 2.59, 95% CI 1.25–5.36, p = 0.011), and the degree of differentiation (OR = 2.65, 95% CI 1.54–4.58, p < 0.001). However, other clinicopathological features, including age (OR = 1.07, 95% CI 0.87–1.32, p = 0.516), gender (OR = 0.95, 95% CI 0.77–1.19, p = 0.668), and histology (OR = 0.72, 95% CI 0.48–1.10, p = 0.128) were not significantly different from high expression of MIAT.Conclusions: Our study showed that overexpression of MIAT is related to poor overall survival and clinicopathological features. MIAT can be considered a novel tumor marker to help diagnose tumors earlier and improve patient prognosis.

Coronary intervention door-to-balloon time and outcomes in ST-elevation myocardial infarction: a meta-analysis

Heart ◽  
2018 ◽  
Vol 104 (16) ◽  
pp. 1362-1369 ◽  
Author(s):  
Chee Yoong Foo ◽  
Kwadwo Osei Bonsu ◽  
Brahmajee K Nallamothu ◽  
Christopher M Reid ◽  
Teerapon Dhippayom ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Short Term ◽  
Percutaneous Coronary ◽  
Short Term Mortality ◽  
St Elevation ◽  
Door To Balloon ◽  
Prehospital Delays ◽  
The Relationship

ObjectiveThis study aims to determine the relationship between door-to-balloon delay in primary percutaneous coronary intervention and ST-elevation myocardial infarction (MI) outcomes and examine for potential effect modifiers.MethodsWe conducted a systematic review and meta-analysis of prospective observational studies that have investigated the relationship of door-to-balloon delay and clinical outcomes. The main outcomes include mortality and heart failure.Results32 studies involving 299 320 patients contained adequate data for quantitative reporting. Patients with ST-elevation MI who experienced longer (>90 min) door-to-balloon delay had a higher risk of short-term mortality (pooled OR 1.52, 95% CI 1.40 to 1.65) and medium-term to long-term mortality (pooled OR 1.53, 95% CI 1.13 to 2.06). A non-linear time–risk relation was observed (P=0.004 for non-linearity). The association between longer door-to-balloon delay and short-term mortality differed between those presented early and late after symptom onset (Cochran’s Q 3.88, P value 0.049) with a stronger relationship among those with shorter prehospital delays.ConclusionLonger door-to-balloon delay in primary percutaneous coronary intervention for ST-elevation MI is related to higher risk of adverse outcomes. Prehospital delays modified this effect. The non-linearity of the time–risk relation might explain the lack of population effect despite an improved door-to-balloon time in the USA.Clinical trial registrationPROSPERO (CRD42015026069).

scholarly journals TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Zhe Chen ◽  
Jiayi Guo ◽  
Kun Zhang ◽  
Yanxing Guo
Keyword(s):  
Overall Survival ◽  
Prognostic Value ◽  
Large Scale ◽  
Meta Analysis ◽  
Published Data ◽  
Tp53 Mutations ◽  
Study Heterogeneity ◽  
Quantitative Synthesis ◽  
Prospective Trials ◽  
The Relationship

Several research groups have examined the association between TP53 mutations and prognosis in human osteosarcoma. However, the results were controversial. The purpose of this study was to evaluate the prognostic value of TP53 mutations in osteosarcoma patients. A meta-analysis was conducted with all eligible studies which quantitatively evaluated the relationship between TP53 mutations and clinical outcome of osteosarcoma patients. Eight studies with a total of 210 patients with osteosarcoma were included in this meta-analysis. The risk ratio (RR) with a 95% confidence interval (95% CI) was calculated to assess the effect of TP53 mutations on 2-year overall survival. The quantitative synthesis of 8 published studies showed that TP53 mutations were associated with 2-year overall survival in osteosarcoma patients. These data suggested that TP53 mutations had an unfavorable impact on 2-year overall survival when compared to the counterparts with wild type (WT) TP53 (RR: 1.79; 95% CI: 1.12 to 2.84;P=0.01;I2=0%). There was no between-study heterogeneity. TP53 mutations are an effective prognostic marker for survival of patients with osteosarcoma. However, further large-scale prospective trials should be performed to clarify the prognostic value of TP53 mutations on 3- or 5-year survival in osteosarcoma patients.

scholarly journals Over-expression of cyclo-oxygenase-2 predicts poor survival of patients with nasopharyngeal carcinoma: a meta-analysis

2020 ◽  
Vol 134 (4) ◽  
pp. 338-343
Author(s):  
C-C Sim ◽  
E U-H Sim
Keyword(s):  
Overall Survival ◽  
Nasopharyngeal Carcinoma ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Meta Analysis ◽  
Survival Outcome ◽  
Poor Survival ◽  
Over Expression ◽  
Relationship Of ◽  
The Relationship

AbstractObjectivesThe conclusive prognostic significance of cyclo-oxygenase-2 has been determined in various cancers but not in nasopharyngeal carcinoma. Therefore, this study aimed to evaluate the relationship of cyclo-oxygenase-2 expression with the survival outcome and treatment response of nasopharyngeal carcinoma patients via a systematic meta-analysis approach.MethodsA meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (‘PRISMA’) checklist. The primary clinical characteristics of patients, and hazard ratios with 95 per cent confidence intervals of overall survival data, were tabulated from eligible studies. The relationship of cyclo-oxygenase-2 expression with survival outcome (expressed as hazard ratio) and treatment response (expressed as odds ratio) in nasopharyngeal carcinoma patients was analysed, and explained with the aid of forest plot charts.Results and conclusionThe pooled hazard ratio for overall survival was 2.02 (95 per cent confidence interval = 1.65–2.47). This indicates that the over-expression of cyclo-oxygenase-2 is significantly associated with the poor survival of nasopharyngeal carcinoma patients. The pooled odds ratio of 0.98 (95 per cent confidence interval = 0.27–3.49) reveals that over-expression of cyclo-oxygenase-2 was not significantly related to the treatment outcome.

scholarly journals Association between alendronate and atypical femur fractures: a meta-analysis

2015 ◽  
Vol 4 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Lu Liu ◽  
Chunyan Li ◽  
Peng Yang ◽  
Jian Zhu ◽  
Dongmei Gan ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Cochrane Library ◽  
Short Term ◽  
Treatment Of Osteoporosis ◽  
Femur Fractures ◽  
Atypical Femur Fractures ◽  
The Subject ◽  
Mean Differences ◽  
The Relationship

Alendronate (ALN) is a commonly used drug for the treatment of osteoporosis. Atypical femur fractures (AFFs) have been associated with long-term use of ALN and have recently become the subject of considerable attention as ALN use increases. This meta-analysis aimed to determine the relationship between ALN and AFF. The Embase, PubMed, and Cochrane library databases were searched for relevant studies published before November 6, 2014. Studies clearly reporting the relationship between ALN and AFF were selected for our analysis. From these results, the relationship between ALN and AFF was analyzed. Weighted mean differences were calculated using a random-effects model. Five studies were included in this meta-analysis. The results revealed that the use of ALN will not increase the risk of AFF in short term (P>0.05), but there will be a risk of AFF (P<0.05) with long-term (>5 years) use of ALN. These findings indicate that long-term use of ALN is a risk factor for AFF and that more attention should be paid to the clinical applications of ALN.

Sign in / Sign up

Export Citation Format

Share Document